{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T17:48:20Z","timestamp":1786297700774,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.msard.2024.106160","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:08:15Z","timestamp":1730808495000},"page":"106160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Early rituximab versus escalating therapy in neuromyelitis optica: A cost and quality of life analysis"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-3763","authenticated-orcid":false,"given":"Guilherme Diogo","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Lu\u00edsa","family":"Ap\u00f3stolos-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Boaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Barbosa","family":"Paolilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena Sales","family":"Pitombeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarso","family":"Adoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.106160_bib0001","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis","volume":"44","author":"Bagherieh","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2024.106160_bib0002","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jval.2024.02.015","article-title":"From health to well-being: toward a monetary valuation of a well-being-adjusted life-year","volume":"27","author":"Brinkmann","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2024.106160_bib0003","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.106160_bib0004","first-page":"46","article-title":"Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides","volume":"44","author":"Guisado-Gil","year":"2020","journal-title":"Farm. Hosp."},{"key":"10.1016\/j.msard.2024.106160_bib0005","doi-asserted-by":"crossref","first-page":"e1184","DOI":"10.1212\/WNL.0000000000200052","article-title":"Costs and health-related quality of life in patients with NMO spectrum disorders and MOG-antibody-associated disease: CHANCENMO study","volume":"98","author":"H\u00fcmmert","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.106160_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200052","article-title":"Costs and health-related quality of life in patients with NMO spectrum disorders and MOG-antibody\u2013associated disease","volume":"98","author":"H\u00fcmmert","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.106160_bib0007","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2024.106160_bib0008","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.106160_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-330714","article-title":"Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum","author":"Park","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2024.106160_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104581","article-title":"Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: a systematic review and meta-analysis","author":"Pipek","year":"2023","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2024.106160_bib0011","first-page":"1","article-title":"The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil","volume":"82","author":"Pipek","year":"2024","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2024.106160_bib0012","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jval.2021.01.012","article-title":"Willingness to pay for health-related quality of life gains in relation to disease severity and the age of patients","volume":"24","author":"Reckers-Droog","year":"2021","journal-title":"Value Health"},{"issue":"Suppl 5","key":"10.1016\/j.msard.2024.106160_bib0013","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/annonc\/mdt326","article-title":"The role of generic medicines and biosimilars in oncology in low-income countries","volume":"24","author":"Renner","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.msard.2024.106160_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JCO.2020.39.28_suppl.73","article-title":"Evaluation of real-world cost savings and utilization of biosimilar drugs in a community-based oncology practice","volume":"39","author":"Sanyal","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.msard.2024.106160_bib0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.106160_bib0016","article-title":"Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in S\u00e3o Paulo, Brazil","volume":"70","author":"Silva","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106160_bib0017","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106160_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578140","article-title":"Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis","volume":"381","author":"Terrim","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2024.106160_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102843","article-title":"Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis","volume":"50","author":"Wang","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106160_bib0020","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.106160_bib0021","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106160_bib0022","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106160_bib0023","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:55:14Z","timestamp":1757357714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824007363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"alternative-id":["S2211034824007363"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106160","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early rituximab versus escalating therapy in neuromyelitis optica: A cost and quality of life analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106160"}}